Abstract
Mechanisms responsible for HIV cardiomyopathy are unknown, but may include direct effects of HIV proteins on the heart. Transgenic mice (TG) expressing HIV Tat protein targeted to the myocardium, +/− Tat TG, have revealed anatomical and biochemical defects in the heart. The present studies were conducted to clarify the effect of Tat on cardiac function. In vivo hemodynamics was measured in awake mice after inserting a catheter tip in the left ventricle under general anesthesia. Under the age of 3 months, the heart rate (HR) was significantly lower in TG (591 ± 47 vs. 716 ± 45 bpm, TG versus FVB control (FVB), respectively (P < 0.05; n = 8–12). Other hemodynamic indexes, including left ventricular systolic pressure (LVSP), positive and negative dp/dt (mmHg/s), and left ventricular end diastolic pressure (LVEDP) remained indistinguishable from FVB. At 6 months, however, ventricular dysfunction was evident in TG (HR = 580 ± 47 vs. 673 ± 25 bpm, TG versus FVB, P < 0.05); LVSP (132 ± 6 vs. 147 ± 6 mmHg, TG versus FVB; P < 0.05); LVEDP (15 ± 4 vs. 8 ± 6 mmHg, TG vs. FVB, P < 0.05); +dp/dt = 8872 ± 331 vs. 10026 ± 796 mmHg/s TG versus FVB, P < 0.01) and −dp/dt (7403 ± 432 vs. 8835 ± 368 mmHg/s, TG versus FVB, P < 0.01; n = 8–12, in each group). The change in percentage of fractional shortening in response to isoproterenol was also significantly reduced in cardiac myocytes isolated from TG versus FVB (P < 0.05). Thus, targeted myocardial transgenic expression of HIV Tat in mice results in relative bradycardia, depression in systolic and diastolic functions in vivo, and blunted adrenergic responsiveness in vitro.
Similar content being viewed by others
References
Calasbrese, L. H., Proffitt, M. R., Yen-Lieberman, B., Hobbs, R. E., & Ratliff, N. B. (1987). Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Annals of Internal Medicine, 107(5), 691–692.
Stewart, J. M., Kaul, A., Gromisch, D. S., Reyes, E., Woolf, P. K., & Gowitz, M. H. (1989). Symptomatic cardiac dysfunction in children with human immunodeficiency virus infection. American Heart Journal, 117(1), 140–144. doi:10.1016/0002-8703(89)90668-6.
Mirri, A., Rapezzi, C., Iacopi, F., Ortolani, P., Binetti, G., Fabbri, M., et al. (1990). Cardiac involvement in HIV infection: A prospective, multicenter clinical and echocardiographic study. Cardiologia (Rome, Italy), 35(3), 203–209.
Coudray, N., de Zuttere, D., Force, G., Champetier de Ribes, D., Pourny, J. C., Antony, I., et al. (1995). Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: An echocardiographic study. European Heart Journal, 16(1), 61–67.
Barbaro, G., Barbarini, G., & Di Lorenzo, G. (1996). Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: A multicenter echocardiographic and echo-Doppler study. The Gruppo Italiano Per lo Studio Cardiologico dei Pazienti Affetti da AIDS. AIDS Research and Human Retroviruses, 12(16), 1559–1563. doi:10.1089/aid.1996.12.1559.
Cardoso, J. S., Moura, B., Martins, L., Mota-Miranda, A., Rocha Gonc̨alves, F., & Lecour, H. (1998). Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. International Journal of Cardiology, 63(1), 37–45. doi:10.1016/S0167-5273(97)00276-3.
Barbaro, G., & Lipshultz, S. E. (2001). Pathogenesis of HIV-associated cardiomyopathy. Annals of the New York Academy of Sciences, 946, 57–81. Review.
Monsuez, J. J., Escaut, L., Teicher, E., et al. (2007). Cytokines in HIV-associated cardiomyopathy. International Journal of Cardiology, 120(2), 150–157. doi:10.1016/j.ijcard.2006.11.143.
Currie, P. F., Goldman, J. H., Caforio, A. L., et al. (1998). Cardiac autoimmunity in HIV related heart muscle disease. Heart (British Cardiac Society), 79(6), 599–604.
Buonaguro, L., Barillari, G., Chang, H. K., et al. (1992). Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. Journal of Virology, 66(12), 7159–7167.
Rerkpattanapipat, P., Wongpraparut, N., & Larry, E. (2000). Cardiac manifestations of acquired immunodeficiency syndrome. Archives of Internal Medicine, 160, 602–608. doi:10.1001/archinte.160.5.602.
Kan, H., Xie, Z., & Finkel, M. S. (2000). HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NF-KB activation. The American Journal of Physiology, 279, H3138–H3143.
Kan, H., Xie, Z., & Finkel, M. S. (2004). P38 MAP kinase mediated negative inotropic effect of HIV gp120 on cardiac myocytes. American Journal of Physiology Cell Physiology, 286(1), C1–C7. doi:10.1152/ajpcell.00059.2003.
Kan, H., Xie, Z., & Finkel, M. S. (2006). IPLA2 inhibitor blocks negative inotropic effect of HIV gp120 on cardiac myocytes. Journal of Molecular and Cellular Cardiology, 40(1), 131–137. doi:10.1016/j.yjmcc.2005.10.006.
Yuan, Y., Kan, H., Fang, Q., Chen, F., & Finkel, M. S. (2008). CXCR4 receptor antagonist blocks cardiac myocyte P38 MAP kinase phosphorylation by HIV gp120. Cardiovascular Toxicology, 8(4), 173–180. doi:10.1007/s12012-008-9026-y.
Chen, F., Shannon, K., Ding, S., Silva, M. E., Wetzel, G. T., Klitzner, T. S., et al. (2002). HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Research and Human Retroviruses, 18(11), 777–784. doi:10.1089/08892220260139512.
Raidel, S. M., Haase, C., Jansen, N. R., & Lewis, W. (2002). Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. American Journal of Physiology. Heart and Circulatory Physiology, 282(5), H1672–H1678.
Rana, T. M., & Jeang, K. T. (1999). Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Archives of Biochemistry and Biophysics, 365(2), 175–185. doi:10.1006/abbi.1999.1206.
Pugliese, A., Vidotto, V., Beltramo, T., et al. (2005). A review of HIV-1 Tat protein biological effects. Cell Biochemistry and Function, 23(4), 223–227. doi:10.1002/cbf.1147.
Wang, Q., Brunner, H. R., & Burnier, M. (2004). Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter. American Journal of Physiology Heart and Circulatory Physiology, 286(2), H806–H814. doi:10.1152/ajpheart.00291.2003.
Kan, H., & Finkel, M. S. (2003). Inflammatory mediators and reversible myocardial dysfunction. Journal of Cellular Physiology, 195, 1–11. doi:10.1002/jcp.10213.
Fan, G.-C., Zhou, X., Wang, X., Song, G., Qian, J., Nicolaou, P., et al. (2008). Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circulation Research, 103, 1270–1279. doi:10.1161/CIRCRESAHA.108.182832.
Singh, I. N., El-Hage, N., Campbell, M. E., et al. (2005). Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons. Neuroscience, 135(3), 781–790. doi:10.1016/j.neuroscience.2005.05.028.
Liu, X., Jana, M., Dasgupta, S., et al. (2002). Human immunodeficiency virus type 1 (HIV-1) Tat induces nitric-oxide synthase in human astroglia. The Journal of Biological Chemistry, 277(42), 39312–39319. doi:10.1074/jbc.M205107200.
Fisher, S. D., Easley, K. A., Orav, E. J., Colan, S. D., Starc, T. J., Bricker, J. T., et al. (2005). Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: The prospective P2C2 HIV multicenter study. American Heart Journal, 150(3), 439–447. doi:10.1016/j.ahj.2005.06.012.
Twagirumukiza, M., Nkeramihigo, E., Seminega, B., Gasakure, E., Boccara, F., & Barbaro, G. (2007). Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: A multicenter, observational, prospective, cohort study in Rwanda. Current HIV Research, 5(1), 129–137. doi:10.2174/157016207779316288.
Kristoffersen, U. S., Lebech, A. M., Gerstoft, J., Hesse, B., Petersen, C. L., Gutte, H., et al. (2008). Right and left cardiac function in HIV-infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: A 5-year follow-up study. HIV Medicine, 9(3), 180–186. doi:10.1111/j.1468-1293.2007.00531.x.
Khunnawat, C., Mukerji, S., Havlichek, D. Jr., Touma, R., & Abela, G. S. (2008). Cardiovascular manifestations in human immunodeficiency virus-infected patients. The American Journal of Cardiology, 102(5), 635–642. doi:10.1016/j.amjcard.2008.04.035.
El Hattaoui, M., Charei, N., Boumzebra, D., Aajly, L., & Fadouach, S. (2008). Prevalence of cardiomyopathy in HIV infection: Prospective study on 158 HIV patients. Medecine et Maladies Infectieuses, 38(7), 387–391. doi:10.1016/j.medmal.2008.03.006.
Otis, J. S., Ashikhmin, Y. I., Brown, L. S., & Guidot, D. M. (2008). Effect of HIV-1-related protein expression on cardiac and skeletal muscles from transgenic rats. AIDS Research and Therapy, 5, 8. doi:10.1186/1742-6405-5-8.
Fiala, M., Popik, W., Qiao, J. H., et al. (2004). HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovascular Toxicology, 4(2), 97–107. doi:10.1385/CT:4:2:097.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fang, Q., Kan, H., Lewis, W. et al. Dilated Cardiomyopathy in Transgenic Mice Expressing HIV Tat. Cardiovasc Toxicol 9, 39–45 (2009). https://doi.org/10.1007/s12012-009-9035-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-009-9035-5